Citrullinated histone H3: a novel target for the treatment of sepsis.
about
PAD4-deficiency does not affect bacteremia in polymicrobial sepsis and ameliorates endotoxemic shockRelease and activity of histone in diseases.Inhibition of peptidylarginine deiminase attenuates inflammation and improves survival in a rat model of hemorrhagic shock.Protective effect of Cl-amidine against CLP-induced lethal septic shock in miceThe role of extracellular histone in organ injury.Consequences of extracellular trap formation in sepsis.CitH3: a reliable blood biomarker for diagnosis and treatment of endotoxic shock.From amino acids polymers, antimicrobial peptides, and histones, to their possible role in the pathogenesis of septic shock: a historical perspective.Complement and sepsis-induced heart dysfunction.Cl-Amidine Prevents Histone 3 Citrullination and Neutrophil Extracellular Trap Formation, and Improves Survival in a Murine Sepsis Model.The Novel HDAC8 Inhibitor WK2-16 Attenuates Lipopolysaccharide-Activated Matrix Metalloproteinase-9 Expression in Human Monocytic Cells and Improves Hypercytokinemia In Vivo.Physiological Levels of Pentraxin 3 and Albumin Attenuate Vascular Endothelial Cell Damage Induced by Histone H3 In Vitro.PAD4 Deficiency Leads to Decreased Organ Dysfunction and Improved Survival in a Dual Insult Model of Hemorrhagic Shock and Sepsis.Depletion of myeloid cells exacerbates hepatitis and induces an aberrant increase in histone H3 in mouse serum.Biology, role and therapeutic potential of circulating histones in acute inflammatory disordersCirculating H3Cit is elevated in a human model of endotoxemia and can be detected bound to microvesicles
P2860
Q35197441-583A33BB-FC9F-4240-BBC9-F9F0257AD309Q35679542-74015F28-D520-4270-9ACE-94EE1F97A82AQ36404947-AC8E6C51-D4E0-4CD1-AEB7-FDF8A832BD9CQ37397289-02DD2B41-EBCA-45F4-B0ED-CE5E13431834Q38679240-01C53DFC-087C-41C9-9D34-65955475CF2CQ39001943-7C76C5DD-AB8F-4F55-8245-607C3A4E1847Q40085091-4F9141AD-38D5-47BD-A09B-4F8AC52B609BQ40331159-C0742040-D238-404F-8453-1A383EC80A91Q40417787-6954A0F5-6AF0-409A-9EBB-66890197ED54Q40542138-E02EDC3E-A2AD-4580-853F-79E4BF4F7D31Q41181662-4A8B797A-E05F-4275-BCF3-B1F2D54A469CQ41948880-80BAE265-14D2-49F5-B473-0A6D80F25C36Q47646315-986C3B8B-3A53-4510-9872-E2838AA27B43Q51369663-39D14C9D-469D-47F5-8ED8-F1AE1053891DQ57141152-D7E0E0C0-2604-4810-84B6-33D74A714EF5Q58714196-66443FB2-1838-4535-8CB4-3F30FD6CEEA8
P2860
Citrullinated histone H3: a novel target for the treatment of sepsis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Citrullinated histone H3: a novel target for the treatment of sepsis.
@ast
Citrullinated histone H3: a novel target for the treatment of sepsis.
@en
type
label
Citrullinated histone H3: a novel target for the treatment of sepsis.
@ast
Citrullinated histone H3: a novel target for the treatment of sepsis.
@en
prefLabel
Citrullinated histone H3: a novel target for the treatment of sepsis.
@ast
Citrullinated histone H3: a novel target for the treatment of sepsis.
@en
P2093
P2860
P1433
P1476
Citrullinated histone H3: a novel target for the treatment of sepsis.
@en
P2093
Baoling Liu
Hasan B Alam
Yanming Wang
Yongqing Li
Zhengcai Liu
P2860
P304
P356
10.1016/J.SURG.2014.04.009
P407
P577
2014-06-21T00:00:00Z